Loading…
Black Diamond Therapeutics, Inc. is projected to rise to $2.63 by 2027, a +14% move from its current price of $2.31. BDTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.18 | $2.31 | $2.45 | +0.06% |
| May 30 | $2.13 | $2.31 | $2.51 | +0.11% |
| May 31 | $2.09 | $2.31 | $2.56 | +0.17% |
| Jun 1 | $2.06 | $2.32 | $2.61 | +0.23% |
| Jun 2 | $2.03 | $2.32 | $2.64 | +0.29% |
| Jun 3 | $2.01 | $2.32 | $2.68 | +0.34% |
| Jun 4 | $1.98 | $2.32 | $2.71 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.98 | $2.32 | $2.71 | +0.40% |
| Week 2 | $1.87 | $2.33 | $2.90 | +0.80% |
| Week 3 | $1.78 | $2.34 | $3.07 | +1.21% |
| Week 4 | $1.72 | $2.35 | $3.21 | +1.61% |
| Week 5 | $1.66 | $2.36 | $3.34 | +2.02% |
| Week 6 | $1.61 | $2.37 | $3.47 | +2.43% |
| Week 7 | $1.57 | $2.38 | $3.59 | +2.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on discovery and development of MasterKey therapies for patients with genetically defined tumors. Its lead product candidate silevertinib is a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
The company is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial, and BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc.
in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Black Diamond Therapeutics, Inc. (BDTX) operates in the Healthcare sector as a clinical-stage oncology company focused on MasterKey therapies.
A major floor 39.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.3% away) — a key level to hold.
The nearest ceiling, 55.8% above — a clean break opens room to run.
A major ceiling 75.3% above — clearing it would confirm fresh momentum.
Key BDTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.81 | Sell | $2.59 | Sell |
| MA 10 | $2.81 | Sell | $2.73 | Sell |
| MA 20 | $2.79 | Sell | $2.78 | Sell |
| MA 50 | $2.64 | Sell | $2.70 | Sell |
| MA 100 | $2.54 | Sell | $2.69 | Sell |
| MA 200 | $2.95 | Sell | $2.76 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.46 | Neutral |
| Stoch RSI (14) | 2.43 | Buy |
| CCI (20) | -132.64 | Sell |
| Williams %R (14) | -97.73 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -22.74 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 2.27 | Buy |
| TRIX (15) | 0.30 | Buy |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 42.00 | Neutral |
| Momentum (10) | -0.52 | Sell |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 2.42 | Sell |
| ADX (14) | 17.54 | Neutral |
| ATR (14) | 0.20 | Info |
Current price: $2.28 per share; market capitalization: $130.65M; rank: 4100.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.03 | $2.31 | $3.58 | 0% | Neutral | |
| $1.89 | $2.63 | $3.95 | +14% | Neutral | |
| $1.59 | $2.34 | $3.75 | +1% | Neutral | |
| $1.69 | $2.63 | $4.40 | +14% | Neutral | |
| $2.09 | $3.40 | $5.93 | +47% | Bullish | |
| $2.67 | $4.54 | $8.19 | +97% | Bullish | |
| $2.64 | $4.68 | $8.70 | +103% | Bullish | |
| $2.53 | $4.67 | $8.91 | +102% | Bullish | |
| $2.57 | $4.94 | $9.67 | +114% | Bullish | |
| $2.21 | $4.40 | $8.82 | +91% | Bullish | |
| $3.23 | $7.19 | $15.81 | +211% | Bullish | |
| $8.61 | $19.14 | $44.03 | +729% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.03 | $2.31 | $2.76 | +0.00% |
| June 2026 | $2.05 | $2.45 | $3.05 | +6.21% |
| July 2026 | $2.00 | $2.43 | $3.10 | -0.80% |
| August 2026 | $1.92 | $2.38 | $3.09 | -2.36% |
| September 2026 | $2.02 | $2.53 | $3.33 | +6.28% |
| October 2026 | $2.12 | $2.67 | $3.58 | +5.91% |
| November 2026 | $2.06 | $2.62 | $3.55 | -2.01% |
| December 2026 | $2.03 | $2.61 | $3.58 | -0.27% |
Click any year to see its month-by-month BDTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BDTX to range from $2.03 to $3.58 through 2026. The $2.31 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BDTX price prediction for 2027 points to an average of $2.63 (low $1.89, high $3.95) — a potential gain of +14% on today's $2.31. Price action looks broadly range-bound.
In 2028, BDTX is projected to trade between $1.59 and $3.75, averaging $2.34 — a potential gain of +1% from today's $2.31. That is -11% versus the projected 2027 average. A consolidation phase looks the most probable path here.
Black Diamond Therapeutics, Inc.'s 2029 outlook centres on $2.63, within a $1.69 to $4.40 range. That is up +12% on the projected 2028 average. That marks a +14% change versus current levels. Price action looks broadly range-bound.
By 2030, BDTX could reach as high as $5.93, with a base case around $3.40 and support toward $2.09 — roughly +47% from $2.31. Buyers look set to stay in control over this stretch.
Expect BDTX to range from $2.67 to $8.19 through 2031. The $4.54 average target implies a +97% move from current prices. That is up +33% on the projected 2030 average. Momentum favours further upside here.
The BDTX price prediction for 2032 points to an average of $4.68 (low $2.64, high $8.70) — a potential gain of +103% on today's $2.31. Buyers look set to stay in control over this stretch.
In 2033, BDTX is projected to trade between $2.53 and $8.91, averaging $4.67 — a potential gain of +102% from today's $2.31. That is 0% versus the projected 2032 average. Momentum favours further upside here.
Black Diamond Therapeutics, Inc.'s 2034 outlook centres on $4.94, within a $2.57 to $9.67 range. That is up +6% on the projected 2033 average. That marks a +114% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BDTX could reach as high as $8.82, with a base case around $4.40 and support toward $2.21 — roughly +91% from $2.31. Momentum favours further upside here.
Expect BDTX to range from $3.23 to $15.81 through 2040. The $7.19 average target implies a +211% move from current prices. That is up +63% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BDTX price prediction for 2050 points to an average of $19.14 (low $8.61, high $44.03) — a potential gain of +729% on today's $2.31. Momentum favours further upside here.
Investing $1,000 in BDTX today (≈ 432.900433 BDTX) could be worth
$8,286.55
+$7,286.55 (+729%) by 2050 · US Dollar
Based on the average projected BDTX price of $19.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDTXwould be worth at today's price.
$1,000 invested in BDTX on May 27, 2025 (≈ 487.804889 BDTX) would be worth
$1,126.83
+$126.83 (+12.7%) today · 1.13× · US Dollar
Based on a BDTX entry price of $2.05 vs. today's $2.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.6 | $641.67 | -35.8% |
| 1 month ago | $2.92 | $791.1 | -20.9% |
| 3 months ago | $2.5 | $924 | -7.6% |
| 6 months ago | $3.82 | $604.71 | -39.5% |
| 1 year ago | $2.05 | $1,126.83 | +12.7% |
| All time (5.0y) ago | $12.61 | $183.19 | -81.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDTX forecast.
Our base-case forecast reaches $4.60 around 2032.
Implied market cap at $4.60: $263.59M
Forecasts show a multi-year bullish trajectory beginning in 2030. The 2030 average price is $3.29 with a max of $5.75 and a min of $2.02, a ROI of 44.5%, and a bullish sentiment. The 2040 forecast lists an average of $6.73 with a max of $14.81, a min of $3.03, a ROI of 195.3%, and bullish sentiment.
The 2050 forecast shows an average of $18.08 with a max of $41.58, a min of $8.13, a ROI of 692.9%, and bullish sentiment. Earlier years balance neutral to bullish momentum, with 2026 average $2.28 (ROI 0) and 2027 average $2.58 (ROI 13.2), 2028 average $2.25 (ROI -1.2), and 2029 average $2.59 (ROI 13.5). These are estimates and not guarantees.
Tap a question to reveal the answer.
2030 average price is $3.29 with a min of $2.02 and a max of $5.75, a ROI of 44.5%, and bullish sentiment.
Forecasts show a bullish path from 2030 onward with higher average prices and ROI (2030 avg $3.29, 2040 avg $6.73, 2050 avg $18.08; 2030 ROI 44.5%, 2040 ROI 195.3%, 2050 ROI 692.9%). Near-term years around 2026-2029 are mixed (e.g., 2026 avg $2.28, ROI 0; 2027 avg $2.58, ROI 13.2; 2028 avg $2.25, ROI -1.2; 2029 avg $2.59, ROI 13.5). These are estimates and not guarantees.
Yes. The 2040 maximum is $14.81 and the 2050 maximum is $41.58, so reaching $10 is within the projected upper bounds.
Current price is $2.28 and market capitalization is $130.65M.
The 30-day technical picture is Bearish with RSI 14 at 40. The SMA50 is $2.63 and the SMA200 is $2.95. Support is at $2.28 and resistance at $3.60, with a 30-day range of $1.51 to $3.45 and annualized volatility of 100%.
Black Diamond Therapeutics, Inc. Community Discussion
0Share your Black Diamond Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.